SeaLife Pharma was founded in 2008 as a marine biotechnology company. Its core competence is finding and developing new anti-infective agents derived from the ocean. Here, SeaLife Pharma is breaking new ground, using a specially developed method for the selective identification of suitable organisms, with a focus on marine microbes.
SeaLife Pharma’s target markets are manufacturers of antibiotic and antifungal agents in Europe and the USA. SeaLife has developed and tested successfully substances that are effective against multiresistant pathogenic bacteria.